COPD in the working age population: The economic impact on both patients and government

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 6, 2013, Pages 629-639

  Van Boven, J F M ^a   Vegter, S ^a   Van Der Molen, T ^b   Postma, M J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Disability; Health economics of COPD; Productivity; Retirement; Tax

Indexed keywords

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST BENEFIT ANALYSIS; HOSPITAL COST; HUMAN; PENSION; PRIORITY JOURNAL; PRODUCTIVITY; RETIREMENT; TAX;

AGE FACTORS; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; EFFICIENCY; FEMALE; HEALTH CARE COSTS; HUMANS; INCOME; MALE; MIDDLE AGED; NETHERLANDS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TAXES;

EID: 84887885439     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.813446     Document Type: Article

References (31)

1. World Health Organization. Chronic obstructive pulmonary disease. Available at http://www.who.int/respiratory/copd/en/Accessed June 2012.
2. National Institute of Public Health and the Environment (RIVM). Available at http://www.nationaalkompas. nl/gezondheid-en-ziekte/ziekten-en-Aandoeningen/ ademhalingswegen/copd/cijfers-copd-prevalentie-incidentieen- sterfte-uit-de-vtv-2010/. Accessed May 2012.
3. Hoogendoorn M, Feenstra TL, Rutten-van Molken MP. Projections of future resource use and the costs of asthma and COPD in the Netherlands. Ned Tijdschr Geneeskd 2006 Jun; 150(22):1243-1250.
4. Average annual earnings per age group, 2010. Central Bureau of Statistics (CBS). Available at: http://statline.cbs.nl/StatWeb/publication/?DM= SLNL&PA=70957NED&D1=1&D2=1- 3&D3=a&D4=0&D5=0,17- 34&D6=l&HDR=G5,G3,G4,G2,T &STB=G1&VW=T. Accessed Oct, 2012.
5. Fletcher MJ, Upton J, Taylor-Fishwick J, Buist SA, Jenkins C, Hutton J, et al. COPD uncovered: an international survey on the impact of chronic obstructive pulmonary disease [COPD] on a working age population. BMC Public Health 2011 Aug; 11:612-2458-11-612.
6. Rutten-van Molken MP, Postma MJ, Joore MA, Van Genugten ML, Leidl R, Jager JC. Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med 1999 Nov; 93(11):779-787.
7. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003 Mar; 97 Suppl C:S3-14.
8. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000 Feb; 117(2 Suppl):5S-9S
9. Hoogendoorn EJI, Feenstra TL, Rutten-van Molken MP. Resource use and costs of care for treating asthma and COPD in the Netherlands. 2004; RIVM report 260604001/2004.
10. Consumer Price Index. Central Bureau of Statistics (CBS). Available at: http://statline.cbs.nl/StatWeb/publication/?DM =SLNL&PA=71311NED&D1= 0&D2=0&D3=64,77,90,103,11 6,129,142,155,168,181,194,219&HDR=G1, T&STB=G2&VW= T. Accessed May 16, 2012.
11. Hoogendoorn M, Feenstra TL, Rutten-van Mlken MPMH. Toekomstprojecties van het zorggebruik en de kosten van astma en COPD in Nederland. Ned Tijdschr Geneeskd 2006; 150:1243-1250.
12. Prescott E, Vestbo J. Socioeconomic status and chronic obstructive pulmonary disease. Th orax 1999 Aug; 54(8):737-741.
13. Heijmans M, Spreeuwenberg P, Rijken PM. NIVEL report. Monitor zorg- en leefsituatie van mensen met astma en mensen met COPD. Trends en ontwikkelingen over de periode 2001-2008. Available from www.nivel.nl. 2009
14. Kremer AM, Pal TM, van Keimpema AR. Employment and disability for work in patients with COPD: a cross-sectional study among Dutch patients. Int Arch Occup Environ Health 2006 Oct; 80(1):78-86.
15. de Graaf R, Tuithof M, van Dorsselaer S, Ten Have M. Comparing the eff ects on work performance of mental and physical disorders. Soc Psychiatry Psychiatr Epidemiol 2012 Nov; 47(11):1873-1883.
16. Oostenbrink J. Guidelines for pharmaco-economic research, actualized version. College voor zorgverzekeringen. Diemen;2006. Available at: http://www.cvz.nl/binaries/live/cvzinternet/hst-content/nl/documenten/ rubriek+zorgpakket/cfh/richtlijnen+farmaco-economisch+onderzoek+-+engels. pdf. Accessed September 15, 2012.
17. Wouters EF. The burden of COPD in The Netherlands: results from the Confronting COPD survey. Respir Med 2003 Mar; 97 Suppl C:S51-9.
18. van den Hout WB. The value of productivity: human-capital versus friction-cost method. Ann Rheum Dis 2010 Jan;69 Suppl 1:i89-91.
19. National disability benefi t expenditures. Central Bureau of Statistics (CBS). Available at: http://statline.cbs.nl/StatWeb/publication/?DM=SLNL&PA= 80905ned&D1=1,4-5&D2=1 29,142,155,168,181&HDR=T&STB=G1&VW=T. Accessed September 21, 2012.
20. Connolly M, Gallo F, Hoorens S, Ledger W. Assessing long-run economic benefi ts attributed to an IVF-conceived singleton based on projected lifetime net tax contributions in the UK. Hum Reprod 2009 Mar; 24(3):626-632.
21. Schofi eld D, Shrestha R, Percival R, Passey M, Callander E, Kelly S. The personal and national costs of CVD: Impacts on income, taxes, government support payments and GDP due to lost labour force participation. Int J Cardiol 2011 Oct 19.
22. Rutschmann OT, Janssens JP, Vermeulen B, Sarasin FP. Knowledge of guidelines for the management of COPD: a survey of primary care physicians. Respir Med 2004 Oct; 98(10):932-937.
23. Barr RG, Celli BR, Martinez FJ, Ries AL, Rennard SI, Reilly JJ, Jr, et al. Physician and patient perceptions in COPD: the COPD Resource Network Needs Assessment Survey. Am J Med 2005 Dec;118(12):1415.
24. Feenstra TL, van Genugten ML, Hoogenveen RT, Wouters EF, Rutten-van Molken MP. The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands. Am J Respir Crit Care Med 2001 Aug; 164(4):590-596.
25. Brouwer WB, Koopmanschap MA. The friction-cost method : replacement for nothing and leisure for free? Pharmacoeconomics 2005; 23(2):105-111.
26. Ahmad S, Billimek J. Limiting youth access to tobacco: comparing the long-term health impacts of increasing cigarette excise taxes and raising the legal smoking age to 21 in the United States. Health Policy 2007 Mar; 80(3):378-391.
27. Hammerlein A, Muller U, Schulz M. Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients. J Eval Clin Pract 2011 Feb; 17(1):61-70.
28. Casas A, Troosters T, Garcia-Aymerich J, Roca J, Hernandez C, Alonso A, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J 2006 Jul; 28(1):123-130.
29. Boyd KA, Briggs AH. Cost-eff ectiveness of pharmacy and group behavioural support smoking cessation services in Glasgow. Addiction 2009 Feb; 104(2):317-325.
30. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term eff ectiveness and cost-eff ectiveness of smoking cessation interventions in patients with COPD. Th orax 2010 Aug; 65(8):711-718.
31. Baldwin M, Williams P, Fletcher MJ, Hutton J, editors. A novel approach to estimate the economic impact of COPD in patients of working age. ; 30 June 2010; ICC, Birmingham, UK: COPD7 International Multidisciplinary Conference; 2010.